PACS1 syndrome is a neurodevelopmental disorder characterized by intellectual disability and craniofacial abnormalities resulting from a de novo p.R203W variant in phosphofurin acidic cluster sorting protein 1 (PACS1). PACS1 is known to play roles in both the endosomal pathway and nucleus, but little is known about how this variant affects the developing nervous system and patients have few therapeutic options. Here, we used stem cell-derived forebrain organoids to show that PACS1(+/R203W) cells share convergent molecular features of autism spectrum disorder (ASD) through a gain-of-function mechanism. These features include an aberrant propensity towards GABAergic differentiation, increased inhibitory synaptic density, and impaired expression of an ASD-specific gene network enriched at synapses. This work is the first to investigate the impact of the p.R203W variant on the developing brain and suggests a therapy that either clears p.R203W PACS1 or targets convergent pathological mechanisms of ASD could be beneficial for patients.